Seropersistence of TBE virus antibodies 10 years after first booster vaccination and response to a second booster vaccination with FSME-IMMUN 0.5 mL in adults

Konior, Ryszard; Brzostek, Jerzy; Poellabauer, Eva-Maria; Jiang, Qin; Harper, Lisa R.; Erber, Wendy N.

doi:10.1016/j.vaccine.2017.03.059

Cited by 29 publications

(23 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Seroresponse rates induced by FSME-IMMUN after the primary vaccination schedule in subjects 70–87 years of age is 99.3% [ 8 ] and there is no evidence that an additional priming dose could be of “immunological” or clinical benefit. Nevertheless, as for other vaccines, antibody titers wane over time [ 9 ]. The excellent boostability of priming with two doses of FSME-IMMUN has been documented for all age groups, including subjects ≥60 years, even as long as 20 years after the last vaccine dose [ 10 ].…”

Section: Discussionmentioning

confidence: 99%

TBE Vaccination Breakthrough Cases—Does Age Matter?

et al. 2021

View full text Add to dashboard Cite

Tick-borne encephalitis (TBE) vaccines are highly effective in preventing TBE and vaccine failures (VF) are rare events. In this study, we compared the age distribution of TBE cases and TBE VF in three endemic countries: Sweden, Southern Germany, and Latvia. While the age distribution of TBE cases was similar for those <50 years versus those ≥50 years in all three countries, in Sweden, a higher proportion of VF cases was ≥50 years, whereas most VF cases in Latvia were <50 years of age and more evenly distributed between those <50 years versus those ≥50 in Southern Germany. Here, theoretical explanations were provided, including differences in diagnostic practices, vaccine uptake between age groups, behavioral patterns and underlying medical conditions, as to why VF were generally older in Sweden than the other countries. There is no scientific rationale to give an extra priming dose of TBE vaccine to subjects ≥50 years of age.

show abstract

Section: Discussionmentioning

confidence: 99%

TBE Vaccination Breakthrough Cases—Does Age Matter?

et al. 2021

View full text Add to dashboard Cite

show abstract

“…It is only in Switzerland that booster injections are recommended every 10 years for all age groups. In adults younger than 50 years, seropersistence of TBE virus antibodies was 88.6% after 10 years subsequent to a three-dose primary series plus a first booster with FSME-Immun [25].…”

Section: Vaccinationmentioning

confidence: 99%

Tick-borne Encephalitis—Need to know for Professionals outside Endemic Areas

Steffen¹

2019

DSAHMJ

View full text Add to dashboard Cite

Tick-borne Encephalitis (TBE) is an arboviral infection widespread in Europe and northern parts of Asia. Ticks transmit the associated flavivirus usually between March and November to people with outdoor activities in the countryside, in gardens or, rarely, in urban parks. The clinical picture of TBE has two phases: after an uncharacteristic febrile illness and a brief interval in which neurological symptoms occur in a minority of the infected patients. In children, meningitis is the predominant syndrome, whereas the proportion of patients with more severe encephalitis and encephalomyelitis increases with growing age. Consequently, children may suffer from cognitive defects and adults from neurological defects after the acute phase. As there is no therapy for TBE, prevention is of paramount importance. The first line of defense is to avoid tick "bites" (actually stings). Various effective and well-tolerated vaccines are marketed in Europe, all parts of Russia, and in China.

show abstract

“…[13][14][15] The vaccine efficacy was assumed to last 10 years after the fourth dose in children and 5 years in the adult cohorts. [26,27] Both vaccines available in Sweden are considered equal immunogenic and interchangeable. [28]…”

Section: Vaccine Efficacymentioning

confidence: 99%